<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02204332</url>
  </required_header>
  <id_info>
    <org_study_id>RLL-CAB-2011-01</org_study_id>
    <nct_id>NCT02204332</nct_id>
  </id_info>
  <brief_title>Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment</brief_title>
  <acronym>COMETA</acronym>
  <official_title>Phase II-b Randomized Study of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinico Universitario de Santiago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Ramón Domínguez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinico Universitario de Santiago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy and safety of cabazitaxel administration
      in patients with colorectal cancer resistant to standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis performed on the first 10 patients showed no efficacy of cabazitaxel
  </why_stopped>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of cabazitaxel measured by estimating the overall response rate (ORR), as the percentage of individuals who achieve a complete tumor response (CR) or partial tumor response (PR) in each arm and between arms.</measure>
    <time_frame>From date of randomization to disease progression or until 24 months from enrolment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From randomisation to either documented disease progression or death from any cause or until 24 months from enrolment (whichever occurs earlier)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization to death from any cause or until 24 months from enrolment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety and toxicity in the experimental arm. Toxicity is graded according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE, v 4.0).</measure>
    <time_frame>From the date the informed consent is signed up to 30 days after the last dose</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel at a dose of 25 mg / m² in a 5% dextrose or 0.9% NaCl intravenously over 1 hour, every 3 weeks (1 cycle).
Besides, patient will be treated with BSC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Supportive Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Best Supportive Care (BSC), with evaluations every 3 weeks (1 cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <other_name>Jevtana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <arm_group_label>Best Supportive Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have given written informed consent.

          -  Men and women aged ≥ 18 years.

          -  Patients with histologically confirmed metastatic advanced colorectal cancer without
             the possibility of potentially curative treatment.

          -  Patients with a life expectancy more than three months.

          -  Patients with advanced colorectal cancer in progression after receiving standard
             treatment.

          -  Patients with grade 0-2 functional status, according to Eastern Cooperative Oncology
             Group (ECOG).

          -  Patients with evaluable tumor by RECIST criteria.

          -  Patients recovered and with a degree less than or equal to 1, or baseline of all
             important pre-treatment-related AEs (excluding alopecia).

          -  Ability and willingness of the patient to consent to participation in the study.

          -  Ability to understand and comply with study procedures.

        Exclusion Criteria:

          -  Patients with a performance status greater than 2, as Eastern Cooperative Oncology
             Group (ECOG).

          -  Inadequate marrow reserve, within 7 days prior to randomization:

               -  absolute neutrophil count &lt;1.5 x 109 / L

               -  Hemoglobin &lt;9.0 g / dL

               -  Platelet count &lt;100 x 109 / L

          -  Inadequate liver function within 7 days prior to randomization:

               -  AST (SGOT) and ALT (SGPT)&gt; 3.0 x ULN or 5&gt; x ULN in case of abnormal liver
                  function due to underlying liver metastases.

               -  Alkaline phosphatase&gt; 3 × ULN (or 5 times the ULN if due to underlying liver
                  metastases).

               -  Total bilirubin&gt; 1.5 x ULN.

          -  Previous history of other malignancy, except for skin basal or squamous cell cancer
             with proper treatment, or in situ cervical cancer, or other cancers, in which the
             patient has been free of the disease in the last 5 years.

          -  Simultaneous treatment with concomitant anticancer therapy.

          -  History of brain metastases, uncontrolled compression of spinal cord, or carcinomatous
             meningitis, or new evidence of brain or leptomeningeal disease pathologies.

          -  Acquired Immunodeficiency Syndrome (AIDS-related diseases) or human immunodeficiency
             virus (HIV) or conditions requiring antiretroviral therapy virus.

          -  symptomatic grade ≥ 2 peripheral sensory neuropathy, according to NCI-CTCAE v4.0.

          -  Any severe acute or chronic medical condition that may affect the patient's ability to
             participate in the study, or may lead to unacceptable security risks and
             non-compliance with protocol procedures or may interfere with the interpretation of
             the study results.

          -  Pregnant women or who are breastfeeding. Pregnancy assessment will be conducted by a
             test serum or urine during the 7 days prior to randomization.

          -  Patient (male or female) of reproductive age who still disagrees with the use of
             effective contraception during the treatment period and for at least 3 months after
             completion of the treatment period of the study. The definition of &quot;effective method
             of birth control&quot; is the opinion of the investigator.

          -  Participation in another clinical trial with an investigational drug and / or an
             investigational drug as adjunctive therapy within 30 days prior to randomization.

          -  Concomitant treatment with prohibited drugs as potent inhibitors or inducers of
             cytochrome P450 3A4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael López López, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinico de Santiago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital German Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lérida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Orense</name>
      <address>
        <city>Orense</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2014</study_first_submitted>
  <study_first_submitted_qc>July 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2014</study_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinico Universitario de Santiago</investigator_affiliation>
    <investigator_full_name>Rafael Lopez Lopez</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

